Empagliflozin for Heart Failure Patients: Expert Insights

Dear Dr. Renukaprasad A R, Are you aware of the clinical benefits of empagliflozin for hemodynamically stable acute heart failure patients? Repeated hospitalization serves as a strong predictor of mortality among heart failure (HF) patients. After discharge, HF patients commonly face readmission within six months, with high mortality rates observed post-one-year. The initiation of empagliflozin treatment for HF patients at hospital discharge has proven effective in reducing all-cause mortality and HF events while enhancing the quality of life. Notably, these benefits remain consistent regardless of the baseline renal function or left ventricular ejection fraction (LVEF). Watch this exclusive video by the expert Cardiologist, Prof. Dr. Giuseppe Rosano, as he presents clinical evidence and discusses the improved outcomes with the use of empagliflozin in HF patients. Watch the Video Highlights: Repeated hospitalization for HF and increased mortality Deviation from guideline-directed medical therapy EMPULSE study Clinical benefits of empagliflozin Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in   |  +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*